Optimal management of a patient with recurrent nasopharyngeal carcinoma (240 views visite)
World Journal Of Clinical Cases (ISSN: 2307-8960), 2014; 2(7): 297-300.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 0.895, 5-year impact factor Impact factor a 5 anni: 1.273
Url: Not available. Non disponibile.
Keywords Parole chiave: Cetuximab, Nasopharyngeal Carcinoma, Re-Irradiation, Surgery Of Metastases, Undifferentiated,
Affiliations Affiliazioni:
*** IBB - CNR ***
Francesco Perri, Francesco Caponigro, Head and Neck Medical Oncology Unit, National Tumor Institute of Naples, 80131 Naples, Italy.
References Riferimenti:
Not available. Non disponibili.
World Journal Of Clinical Cases (ISSN: 2307-8960), 2014; 2(7): 297-300.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 0.895, 5-year impact factor Impact factor a 5 anni: 1.273
Url: Not available. Non disponibile.
Keywords Parole chiave: Cetuximab, Nasopharyngeal Carcinoma, Re-Irradiation, Surgery Of Metastases, Undifferentiated,
Affiliations Affiliazioni:
*** IBB - CNR ***
Francesco Perri, Francesco Caponigro, Head and Neck Medical Oncology Unit, National Tumor Institute of Naples, 80131 Naples, Italy.
References Riferimenti:
Not available. Non disponibili.
Optimal management of a patient with recurrent nasopharyngeal carcinoma
Nasopharyngeal carcinoma is rare in western countries, accounting for less than 1% of all malignancies. Despite prognosis is satisfactory for newly diagnosed, non-metastatic disease, management of recurrent disease is challenging, with a survival expectancy of approximately 6 mo with the use of chemotherapy as the sole salvage treatment. We report a case of recurrent nasopharyngeal carcinoma treated with a combination of chemotherapy, radiotherapy and surgery in the context of a multidisciplinary approach. A durable complete response was achieved.
Nasopharyngeal carcinoma is rare in western countries, accounting for less than 1% of all malignancies. Despite prognosis is satisfactory for newly diagnosed, non-metastatic disease, management of recurrent disease is challenging, with a survival expectancy of approximately 6 mo with the use of chemotherapy as the sole salvage treatment. We report a case of recurrent nasopharyngeal carcinoma treated with a combination of chemotherapy, radiotherapy and surgery in the context of a multidisciplinary approach. A durable complete response was achieved.
Optimal management of a patient with recurrent nasopharyngeal carcinoma
No results. Nessun risultato. |
Optimal management of a patient with recurrent nasopharyngeal carcinoma
Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S, Solla R
* Management of recurrent nasopharyngeal carcinoma: current perspectives (131 visite)
Oncotargets Ther (ISSN: 1178-6930linking), 2019 Feb 26; 12: 1583-1591.
Impact Factor: 2.272
Dettagli Esporta in BibTeX Esporta in EndNote
Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S
* Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications (361 visite)
Head Neck-J Sci Spec (ISSN: 1043-3074), 2015; 37(5): 763-770.
Impact Factor: 2.76
Dettagli Esporta in BibTeX Esporta in EndNote
Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani BM, Parsons SJ, De Placido S, Bianco R
* Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models (332 visite)
Breast Cancer Res Biomed Central Ltd (ISSN: 1465-5411), 2014; 16(3): R45-R45.
Impact Factor: 0.635
Dettagli Esporta in BibTeX Esporta in EndNote
Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marf G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R
* Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models (410 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2013 Jan 1; 19(1): 138-147.
Impact Factor: 8.193
Dettagli Esporta in BibTeX Esporta in EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (351 visite)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
Dettagli Esporta in BibTeX Esporta in EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (363 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M
* PET/CT in cancer research: From preclinical to clinical applications (521 visite)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Impact Factor: 4.02
Dettagli Esporta in BibTeX Esporta in EndNote
Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P
* Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death (413 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2010 Feb 26; 285(9): 6563-6572.
Impact Factor: 5.328
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, Nicolai E, Salvatore M
* [18F]FDG-PET-CT for early monitoring of tumor response: When and why (307 visite)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2009 Apr; 53(2): 167-180.
Impact Factor: 1.724
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (509 visite)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L
* Cetuximab is an active treatment of metastatic and chemorefractory thymoma (311 visite)
Frontiers In Bioscience (ISSN: 1093-9946, 1093-4715), 2007 Jan 1; 12(2): 757-761.
Impact Factor: 2.989
Dettagli Esporta in BibTeX Esporta in EndNote
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S, Solla R
* Management of recurrent nasopharyngeal carcinoma: current perspectives (131 visite)
Oncotargets Ther (ISSN: 1178-6930linking), 2019 Feb 26; 12: 1583-1591.
Impact Factor: 2.272
Dettagli Esporta in BibTeX Esporta in EndNote
Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S
* Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications (361 visite)
Head Neck-J Sci Spec (ISSN: 1043-3074), 2015; 37(5): 763-770.
Impact Factor: 2.76
Dettagli Esporta in BibTeX Esporta in EndNote
Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani BM, Parsons SJ, De Placido S, Bianco R
* Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models (332 visite)
Breast Cancer Res Biomed Central Ltd (ISSN: 1465-5411), 2014; 16(3): R45-R45.
Impact Factor: 0.635
Dettagli Esporta in BibTeX Esporta in EndNote
Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marf G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R
* Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models (410 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2013 Jan 1; 19(1): 138-147.
Impact Factor: 8.193
Dettagli Esporta in BibTeX Esporta in EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (351 visite)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
Dettagli Esporta in BibTeX Esporta in EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (363 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M
* PET/CT in cancer research: From preclinical to clinical applications (521 visite)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Impact Factor: 4.02
Dettagli Esporta in BibTeX Esporta in EndNote
Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P
* Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death (413 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2010 Feb 26; 285(9): 6563-6572.
Impact Factor: 5.328
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, Nicolai E, Salvatore M
* [18F]FDG-PET-CT for early monitoring of tumor response: When and why (307 visite)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2009 Apr; 53(2): 167-180.
Impact Factor: 1.724
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (509 visite)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L
* Cetuximab is an active treatment of metastatic and chemorefractory thymoma (311 visite)
Frontiers In Bioscience (ISSN: 1093-9946, 1093-4715), 2007 Jan 1; 12(2): 757-761.
Impact Factor: 2.989
Dettagli Esporta in BibTeX Esporta in EndNote
11 Records (10 escludendo Abstract e Conferenze).
Impact factor totale: 36.738 (36.103 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 36.917 (36.342 escludendo Abstract e Conferenze).
Impact factor totale: 36.738 (36.103 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 36.917 (36.342 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Raffaele Berisio on in data Sunday 12 July 2020, 13:14:52
240 views visite. Last view on Ultima visita in data Tuesday 19 January 2021, 11:42:40
ibb.cnr.it